PLUS1
1.58
-0.11 (-6.51%)
-0.11 (-6.51%)
Upgrade to Real-Time
Regular Market
Best deals to access real time data! |
|
CHART Trader
Monthly Subscription
for only
|
|
Canadian Level 1 + USA
Monthly Subscription
for only
|
|
Small Cap Basic
Monthly Subscription
for only
|
|
VAT not included
|
| Company Name | Stock Ticker Symbol | Market | Type |
|---|---|---|---|
| AzurRx BioPharma Inc | AZRX | NASDAQ | Common Stock |
| Price Change | Change Percent | Stock Price | Last Traded  |
|
|---|---|---|---|---|
| -0.11 | -6.51% | 1.58 | 09:58:03 |
| Open Price | Low Price | High Price | Close Price | Prev Close |
|---|---|---|---|---|
| 1.66 | 1.56 | 1.66 | 1.69 |
| Bid Price | Ask Price | Spread | News | |
|---|---|---|---|---|
| 1.57 | 1.58 | 0.01 | 1 | - |
| Trades | Volume | VWAP | Dollar Volume | Avg Volume | 52 Week Range |
|---|---|---|---|---|---|
| 654 | 418,784 | $ 1.62 | $ 676,938 | 12,151,250 | 0.370868 - 2.63 |
| Last Trade Time | Type | Quantity | Stock Price | Currency |
|---|---|---|---|---|
| 09:58:03 | 100 | $ 1.58 | USD |
AzurRx BioPharma Financials
| Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
|---|---|---|---|---|---|---|
| $ 54.27M | 34.35M | 33.36M | $ - | $ - | -0.70 | -2.10 |
| Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
|---|---|---|---|---|---|
| - | $ - | 0.00% | - | - |
AzurRx BioPharma News
| Date | Time | Source | News Article |
|---|---|---|---|
| 2/25/2021 | 08:18 | Edgar (US Regulatory) | Current Report Filing (8-k) |
| 2/17/2021 | 09:02 | Edgar (US Regulatory) | Prospectus Filed Pursuant to Rule 424(b)(3) (424b3) |
| 2/17/2021 | 06:07 | Edgar (US Regulatory) | Notice of Effectiveness (effect) |
| 2/16/2021 | 08:02 | Edgar (US Regulatory) | Current Report Filing (8-k) |
| 2/11/2021 | 17:23 | Edgar (US Regulatory) | Securities Registration Statement (simplified Form) (s-3/a) |
| 2/10/2021 | 09:55 | Edgar (US Regulatory) | Amended Statement of Beneficial Ownership (sc 13d/a) |
| 2/09/2021 | 09:02 | Seeking Alpha | AzurRx BioPharma jumps 18% over formulation trial for.. |
|
|
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical AZRX Price Data
| Period | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
|---|---|---|---|---|---|---|---|
| 1 Week | 1.70 | 1.7359 | 1.2536 | 1.61 | 2,140,702 | -0.12 | -7.06% |
| 1 Month | 1.7383 | 2.05 | 1.2536 | 1.66 | 4,387,632 | -0.1583 | -9.11% |
| 3 Months | 0.7845 | 2.63 | 0.7301 | 1.58 | 8,494,643 | 0.7955 | 101.4% |
| 6 Months | 0.8057 | 2.63 | 0.6501 | 1.56 | 3,829,740 | 0.7743 | 96.1% |
| 1 Year | 0.84 | 2.63 | 0.370868 | 1.51 | 2,046,971 | 0.74 | 88.1% |
| 3 Years | 2.82 | 3.75 | 0.370868 | 1.50 | 813,917 | -1.24 | -43.97% |
| 5 Years | 5.06 | 5.60 | 0.370868 | 1.54 | 571,596 | -3.48 | -68.77% |
AzurRx BioPharma Description
| AzurRx BioPharma Inc is a development stage biopharmaceutical company. The company is focused on the development of recombinant proteins for the treatment of gastrointestinal diseases and microbiome-related conditions. Its lead product candidate is MS1819, a yeast-derived recombinant lipase for exocrine pancreatic insufficiency (EPI) associated with cystic fibrosis (CF) and chronic pancreatitis (CP). |
